Clinical Trial Update: Donor Enriched Activated NK Cell Infusion Post Haploidentical Stem Cell Transplant for Refractory Myeloid Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating donor-enriched activated natural killer (NK) cell infusions after haploidentical stem cell transplant for refractory myeloid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• Donor Enriched Activated NK Cell Infusion

Snippet

Sponsor: University of Nebraska | Conditions: Leukemia | Phase 1 | Status: WITHDRAWN